Biogen Has Agreed To Acquire Human Immunology Biosciences For $1.15B Upfront And Up To $650M In Potential Milestone Payments
Biogen Has Agreed To Acquire Human Immunology Biosciences For $1.15B Upfront And Up To $650M In Potential Milestone Payments
Biogen已同意以11.5億美元的預付金和高達6.5億美元的潛在里程碑付款收購人類免疫學生物科學
- Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseases
- Felzartamab is an investigational anti-CD38 monoclonal antibody that, through its cell depletion approach, has demonstrated clinical proof of concept in rare immune-mediated indications, with plans to advance to Phase 3
- Proposed acquisition builds on Biogen capabilities in immunology with plans to combine Human Immunology Biosciences expertise in immune-mediated indications with Biogen's global development and commercial experience in rare diseases
- 該交易將包括費爾扎他單抗，這是一種潛在的同類首創候選治療藥物，有望成爲一系列免疫介導疾病的管道產品
- Felzartamab是一種在研的抗CD38單克隆抗體，通過其細胞耗盡方法，已在罕見的免疫介導適應症中證明了臨床概念的證實，並計劃進入3期
- 擬議的收購建立在Biogen在免疫學領域的能力基礎上，並計劃將人類免疫學生物科學在免疫介導適應症方面的專業知識與Biogen在罕見疾病領域的全球開發和商業經驗相結合
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。